<DOC>
	<DOCNO>NCT01430819</DOCNO>
	<brief_summary>The aim study evaluate safety immunogenicity 2011-2012 formulation Fluzone Fluzone High-Dose vaccine participant age 65 year old . Objectives : - To describe safety Fluzone vaccine Fluzone High-Dose vaccine among adult ≥ 65 year age . - To describe immunogenicity Fluzone vaccine Fluzone High-Dose vaccine among adult ≥ 65 year age .</brief_summary>
	<brief_title>Study Fluzone® Influenza Virus Vaccine 2011-2012 Formulation ( Intramuscular Route ) Among Adults</brief_title>
	<detailed_description>Historically , annual safety immunogenicity study Fluzone vaccine conduct US support license hold sanofi pasteur various country . Participants randomize receive dose either Fluzone® Fluzone® High-Dose vaccine follow safety immunogenicity . The duration participation trial approximately 1 month .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject ≥ 65 year age day inclusion . Informed consent form ( ICF ) sign date . Able attend schedule visit comply trial procedure . History serious adverse reaction influenza vaccine . Receipt vaccine within 30 day receive study vaccine , plan receive another vaccine 2nd visit . Participation another interventional clinical trial investigate vaccine , drug , medical device , medical procedure 30 day precede first study vaccination course study , unless intervention study occur within 30 day prior first study vaccination none plan subject would complete safety surveillance present study . Influenza vaccination 6 month precede enrollment study . Known systemic hypersensitivity egg , chicken protein , latex , vaccine component , history lifethreatening reaction Fluzone Fluzone HighDose vaccine vaccine contain substance ( complete list vaccine component include Investigator 's Brochure and/or package insert ) . Receipt immune globulin , blood , bloodderived product past 3 month . Thrombocytopenia , may contraindication intramuscular ( IM ) vaccination , discretion Investigator . Bleeding disorder receipt anticoagulants 3 week precede inclusion , may contraindication IM vaccination , discretion Investigator . Any condition opinion Investigator would pose health risk subject enrol could interfere evaluation vaccine . Personal history GuillainBarré syndrome . Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) . Chronic illness , opinion Investigator , stage might interfere trial conduct completion . Seropositivity human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C , report subject . Deprived freedom administrative court order , emergency setting , hospitalize involuntarily . Current alcohol drug addiction , opinion Investigator , might interfere ability comply trial procedure . Moderate severe acute illness/infection ( accord Investigator judgment ) febrile illness ( temperature ≥ 38.0°C [ ≥ 100.4°F ] ) day vaccination . A prospective subject include study condition resolve febrile event subside . Identified Investigator employee Investigator study center direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza Virus Vaccine</keyword>
	<keyword>Fluzone® 2011-2012 Formulation</keyword>
	<keyword>Fluzone® High-Dose 2011-2012 Formulation</keyword>
	<keyword>Trivalent Inactivated Influenza Vaccine</keyword>
</DOC>